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Synovial sarcoma comprises approximately 10% of all soft tissue sarcoma diagnoses; a primary synovial sarcoma of the my-
ocardium is exceedingly rare. There have been very few cases reported in the literature thus far. With the identiﬁcation of the
characteristic and diagnostic chromosomal abnormality t(X;18), this may become an increasingly recognized entity. Our report
adds to the limited published cases of primary cardiac synovial sarcoma with the characteristic t(X;18). Further elucidation of the
eﬀects of this translocation on the cell cycle may lead to directed therapies in the future.
Copyright © 2007 Brian Boulmay et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
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1. INTRODUCTION
Synovial sarcoma is an uncommon malignancy, compris-
ing approximately 10% of all soft-tissue sarcomas (STS)
[1]. Unlike other STS, the synovial type occurs most of-
ten in children and young adults and is an aggressive tu-
mor with 10-year-old survival rates reported in some series
as low as 0–20% [2, 3]. It is divided into three subtypes:
biphasic, monophasic and poorly diﬀerentiated. Historically
these nonspeciﬁc histologic characteristics have made the
establishment of a deﬁnitive diagnosis problematic. How-
ever, a characteristic chromosomal abnormality for synovial
sarcoma has been identiﬁed for all morphologic subtypes:
t(X;18) [4].
Primary cardiac synovial sarcoma with the characteristic
t(X;18)hasrarelybeenreportedinthemedicalliterature(see
Table 1)[ 5–10]. We report a recent case from Shands Hospi-
tal at the University of Florida.
2. CASE REPORT
The patient is a 19-year-old woman who had complaints
consisting of shortness of breath, vague chest pain, and in-
creasing exercise intolerance over three months. One week
prior to admission, she noted intermittent palpitations and
the onset of new bilateral lower extremity edema. Physi-
cal examination was signiﬁcant for a 2/6 pansystolic mur-
mur heard at the right lower sternal border and trace pit-
ting lower extremity edema. Continuous ECG monitoring
demonstrated intermittent four to ﬁve beat runs of ventricu-
lar tachycardia.
A computed tomography scan of the chest and abdomen
showed an enlarged heart with a lobulated mass in the right
ventricle. A right-sided pleural eﬀusion, two enlarged inter-
nal mammary lymph nodes, and multiple scattered bilat-
eral pulmonary nodules were also noted. A two dimensional
echocardiogram with doppler conﬁrmed that the right ven-
tricle was essentially ﬁlled with mass. A second mass was
noted to arise from the tricuspid annulus causing severe tri-
cuspid regurgitation and obstructing right ventricular in-
ﬂow.
The decision was made to perform a deﬁnitive resection,
both for diagnosis and restoration of hemodynamic stability.
Preoperatively, cardiac magnetic resonance imaging demon-
strated a bilobed mass within the heart (see Figures 1, 2,a n d
3). One mass was found to ﬁll the right ventricle with exten-
sion into the right ventricular outﬂow tract and pulmonary
artery. Also conﬁrmed was a mass involving the tricuspid
valve, resulting in marked regurgitation with right atrial and
inferior vena cava distension.2 Sarcoma
Table 1
Author Age Sex Cytogenetics Treatment Site of tumor Follow-up
Karn [7]3 5 M t(X;18) Surgery and chemotherapy RA and pericardium Died at 9 months
Iyengar [6]3 8 M t(X;18)der7 Surgery RV Died at 1 year
Oizumi [10]1 9 F t(X;18) Surgery Pericardium Died at 7 months
Al-Rajhi [9]1 9Mt(X;18) RT Pericardium Alive at 12 months
McGilbray [8]3 0 M t(X;18) Surgery and chemotherapy Mitral valve N.A.
Hazelbag [5]4 2 M
61,Y,der(X)t(X;18)(p1;p1)x2,
der(1)t(1;8)(q10;q10),
der(4)t(4;14)(p14;q11∼12),
+5,−6,del(7)(p13∼14),
−9,−10,−11,
der(11)t(11;12)(q10;p10)x2,
der(12)t(X;12)(p;q),−13,
−14,−16,+17,−18,
del(18)(p10),−20,−21,
der(22)t(12;22)(q12;q12)t(11;
12)(q24∼25;q24),
der(22)t(5;22)(p10;
p11)x2[cp25]
Surgery LA/LV, lung/liver mets Died at 1 month
Current case 19 F
49,X,t(X;18)(p11.2;q11.2),
+4,+7,+8,der(13;15)(q10:q10),
+14(20)
Surgery RA/RV, lung metastasis Alive at 4 months
AV
Figure 1: Short axis view shows a large tumor ﬁlling almost the
entire right ventricle (V).
3. OPERATIVE FINDINGS
Sternotomy was performed and as the right hemithorax was
entered, multiple nodules were noted on the visceral and
parietal pleural surfaces. A right middle lobe and hilar lesion
were resected. The heart was inspected and tumor was seen
through the epicardial surface between the right atrium and
aorta. After entering the right atrium, tumor was noted to
be growing from the tricuspid annulus and this was resected
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Figure 2: White blood 4 chamber view shows bilateral pleural eﬀu-
sions, pericardial eﬀusion, right atrial and right ventricular enlarge-
ment. There is a multilobed tumor mass in the right atrium (A) and
right ventricle (V).
down to the right atrial wall. A 2 × 2.5cm portion of tumor
was left on the atrial septum to preserve tricuspid function.
Next, the pulmonary artery was entered and tumor was re-
sected back through the pulmonic valve to the level of the
myocardium. A small portion of tumor was left at the crista
terminalis measuring approximately 1.5cm.
4. PATHOLOGIC FINDINGS
Theintraoperativefrozensectionfrombothlungandcardiac
masses showed a “high-grade sarcoma.” On deﬁnitive patho-
logic examination, the tumor appeared to have features of aBrian Boulmay et al. 3
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Figure 3: Post-gadolinium infusion delayed enhancement study re-
veals signiﬁcant uptake of gadolinium consistent with edema, ﬁbro-
sis or scar.
high-grade synovial sarcoma. Immunohistochemical stain-
ing showed that the tumor was CD99 and BCL-2 positive
further suggesting that this was a synovial sarcoma. Cytoge-
netics were obtained which showed the following karyotype:
49,X,t(X;18)(p11.2;q11.2),+4,+7,+8,der(13;15)(q10:q10),
+14(20). The t(X;18)(p11.2;q11.2) conﬁrmed the diagnosis
of synovial sarcoma.
5. CLINICAL OUTCOME
The patient was discharged on post-operative day nine with
no complication. She had experienced marked improvement
in her shortness of breath. She elected not to pursue pallia-
tive chemotherapy and at four months of follow-up retained
good functional status with no symptoms.
6. DISCUSSION
Thedesignation“synovial”sarcomaimpliesoriginfromnor-
mal synovium. As alluded to previously, it is histologically
described as having a biphasic appearance consisting of two
distinct morphologic subtypes: spindle and epitheliod cell
subtypes. Interestingly, neither epithelial diﬀerentiation nor
IHCstainingforepithelialmarkerslikecytokeratinarefound
in normal synovium. The true tissue of origin is, therefore,
still unknown. Synovial sarcoma occurs primarily in the ex-
tremities and is associated with the large joints, such as the
knee. Contrary to what would be expected, these tumors are
rarelypresentinsidethejointcapsule.Instead,theyarefound
most often in association with bursae and tendon sheaths.
Synovial sarcomas can also be found in structures without a
joint capsule such as in the head and neck and in lung [11].
Primary cardiac synovial sarcomas are exceedingly rare.
Primary cardiac sarcomas of all types have poor out-
comes;primarycardiacsynovialsarcomaisnodiﬀerent,with
a mean survival of 9 to 16.5 months [12]. In the cases of
synovial sarcoma for which outcomes are reported, all but
one patient died within 1 year. A possible exception to this
uniformly poor prognosis has been reported by Sassani et al.
[12].Theydescribethecaseofa45-year-oldmanwitharight
atrial mass who had complete surgical resection. The tumor
was a biphasic synovial sarcoma, however, conﬁrmatory cy-
togenetics could not be performed due to ﬁxative technique.
No adjuvant chemotherapy was given and at 5 years the pa-
tient was reported to be alive [12].
The characteristic chromosomal abnormality of synovial
sarcoma is t(X;18)(p11.2;q11.2) and is present in 90–100%
cases, suggesting strongly that it is directly involved in some
aspect of the malignant process [13, 14]. The t(X;18) fuses
two genes, SYT at 18q11 and SSX at Xp11. The protein prod-
ucts of both of these two genes are transcription regulators
present in the cell nucleus. The normal SSX codes for a pro-
tein that inhibits transcription; SYT on the other hand en-
codes a protein that acts as a transcriptional activator [15].
The t(X;18) results in a replacement of the inhibitor region
of SSX with the activator portion of SYT. Although the genes
normally repressed by SSX are not well described, the fu-
sion protein SYT/SSX likely acts as a transcription derepres-
sor [14]. SYT/SSX is also thought to regulate chromatin re-
modeling which may lead to enhanced proliferation of mes-
enchymal cells [16].
Standardtherapyforsynovialsarcomaclassicallyinvolves
cytotoxic therapy. As compared to other soft tissue sarcomas,
the synovial subtype is relatively chemosensitive; response
r a t e sa sh i g ha s5 8 %a r er e p o r t e di ns o m es e r i e s[ 17]. Ifos-
famide and adriamycin have shown the most consistent eﬃ-
cacy in synovial sarcoma of all chemotherapy drugs used in
softtissuesarcomas,includinggemcitabine,docetaxel,borte-
zomib, imantinib, and others [18]. However, both of these
agents are toxic and in the metastatic setting there is no
standard therapy that is clearly superior to others. The need
for novel therapeutic agents in this disease is clear and the
translocation t(X;18) with the resulting SYT/SSX fusion pro-
tein makes synovial sarcoma an ideal candidate for molec-
ular targeting. The ambiguous function of the fusion pro-
tein leaves much to be done before development of targeted
therapy is completed. Some work has been done using im-
munotherapy to target the SYT/SSX fusion protein. Patients
with synovial sarcoma often have cytotoxic lymphocytes spe-
ciﬁc for the SYT/SSX protein [19]. A phase I study using
an SYT/SSX derived junction peptide vaccine in six patients
with synovial sarcoma has demonstrated some eﬃcacy [20].
The case that we present is unusual in that in addition to
t(X;18) there are ﬁve more cytogenetic abnormalities. Only
two cases in the literature of cardiac synovial sarcoma with
a reported t(X;18) have had complex abnormalities; the ﬁrst
involved chromosome 7 [6] and the second reported a com-
plex karyotype [5]. In cases of noncardiac synovial sarco-
mas, the majority have a diploid or near diploid karyotype.
Retrospective data have shown that patients with synovial
sarcoma and complex chromosomal abnormalities have a
greater tendency to metastasize; this is consistent with the
view that with tumor progression comes additional genetic
abberations[13].Asmoreprimarycardiacsynovialsarcomas
are reported perhaps these tumors will be found more likely
to have complex cytogenetics as compared to the extremity
type.4 Sarcoma
7. CONCLUSION
We have reported a patient with primary cardiac synovial
sarcoma presenting in the right atrium and ventricle with
the characteristic t(X;18)(p11.2;q11.2) and additional cyto-
genetic abnormalities. This complex karyotype has previ-
ously been reported twice in the literature. Synovial sarcoma
of the heart is extremely rare and typically not included in
the diﬀerential diagnosis of cardiac masses. Often the diag-
nosis may be missed due to the nonspeciﬁc histologic and
immunohistochemicalcharacteristicsofatumorwhichoften
maybelabeledasa“poorlydiﬀerentiated”sarcoma.Theclin-
ical outcomes are universally poor despite aggressive thera-
pies. The detection of t(X;18)(p11.2;q11.2) can be a useful
adjuncttothework-upofacardiacsarcoma.Thetherapeutic
implications of establishing a ﬁrm diagnosis may be impor-
tant in the future if targeted therapies become available.
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